ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Is a Good Night's Sleep at the Top of Your Wishlist?

Ashwagandha Helps Hormones - Aids Arthritis

Why You Should Be Eating More Porcini Mushrooms

A Breathalyzer for Disease?

How Bacopa Can Help Improve Your Cognitive Function

Magnesium Reduces Diabetes and Helps Keep You Young

Lavender Aromatherapy Can Ease Pre-Op Anxiety

Give Your Health a Much-Needed Boost With Geranium

The Role of Resveratrol in Achieving Optimal Health

Could Coconut Oil Help Reduce Antibiotics?

 
Print Page
Email Article

Multinational Phase III Trial of Dopamine Drug Rotigotine Reports “Highly Significant” Reduction of Restless Legs Syndrome Symptoms

  [ 669 votes ]   [ Discuss This Article ]
By Editor • www.ProHealth.com • October 18, 2006


Findings of a large multinational phase III trial of the drug rotigotine indicate it “has shown a clinically relevant and highly statistically significant reduction of RLS [Restless Legs Syndrome] symptoms versus placebo in both primary variables.” The six-month trial, which also indicated that rotigotine was “well tolerated” by study participants, is proceeding to a second phase III trial in patients with moderate to severe RLS, according to its maker – the German firm Schwarz Pharma – in a report on October 9, 2006. The results of this second phase III trial are due in first quarter 2007.

Rotigotine is a nonopioid drug designed to mimic the action of dopamine (called a dopamine “agonist”) - which the body produces naturally to support transmission of messages, or “nerve signaling,” in the central nervous system, and thus proper motor functioning. Administered via once-daily application of a transdermal patch (i.e., absorbed through the skin), rotigotine is designed to support a steady level of medication in the system. It is proposed that this may be one benefit of the drug versus other dopamine-agonist therapies for RLS which are delivered via the digestive tract in pill or capsule form.

RLS, also known as Ekbom’s syndrome, is believed to be a metabolic disorder of the nervous system linked to dopamine abnormalities, according to WebMD’s eMedicine Clinical Knowledge Base (http://www.emedicine.com/neuro/topic509.htm). It involves unpleasant crawling or tingling sensations, creating an “irresistible” urge to move the legs. Diagnosed in many patients with FM and CFS, the syndrome's symptoms are felt particularly in the evening and at night when the patient is inactive - and therefore interfere with rest and refreshing sleep, with resulting daytime fatigue.

The “variables” that the trial tested were improvements in symptom severity measured subjectively at the start of the trial or “baseline” and the end of the trial, using:

n The patient’s own assessment of the severity of multiple symptoms on the International Restless Legs Syndrome Study Group Rating Scale (IRLS).1 See a copy of this self-assessment form at http://www.mdvu.org/pdf/rls_rs.pdf)

n And the clinician-assessed score for Item 1 (severity of illness) on the Clinical Global Impression Scale. The CGI scale is commonly used to assess treatment response in drug effectiveness trials.

The trial included 458 patients with moderate to severe RLS, treated in a double-blind, placebo-controlled phase III study. All patients began the three-week titration period at a daily dose of 2.25 mg rotigotine transdermal patch or placebo (fake dose). During the six-month period of treatment, the patients received rotigotine transdermal patch (either 2.25, 4.5, or 6.75 mg per day) or a placebo patch on a daily basis. The most common side effects were application site reactions, nausea, headache, and fatigue.

Rotigotine has already undergone a series of trials for treatment of Parkinson’s disease, another dopamine-related condition. Parkinson’s is caused by an inability to produce quantities of dopamine sufficient to support normal motor function. Rotigotine is now approved for treatment of Parkinson’s patients in Europe, and is under FDA review for approval as a treatment for that condition in the United States.

Other dopamine-related nonopioid drugs employed for treatment of RLS are ropinirole, approved by the FDA for Parkinson’s in 1997 and for RLS in 2005; and pramipexole (Mirapex,R Sifrol,R MirapexenR in the EU), recommended for approval in the EU in February 2006 and with FDA approval possible by year-end 2006.2,3,4 These are delivered via the digestive system rather than via transdermal patch.

In many cases, RLS apparently runs in families. It is a chronic disease that progresses slowly, and occurs in up to 10 percent of the population – about as frequently as migraine and diabetes.

________

1. Abstract: “Validation of the International Restless Legs Syndrome Study Group Rating Scale for Restless Legs Syndrome,” by AS Walters, et al., Sleep Medicine, 2003 Mar; 4(2):121-32; PMID: 14592342

2. Abstract: “A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with Fibromyalgia receiving concomitant medications,” http://www.immunesupport.com/library/showarticle.cfm/id/6608

3. “Pramipexole Delivered Sustained Efficacy in Clinical Trial of Patients with Restless Legs Syndrome,” http://www.immunesupport.com/library/showarticle.cfm/id/6892

4. “Symptom Improvements with Parkinson's Drug Mirapex Found in Fibromyalgia Trial,” http://www.immunesupport.com/library/showarticle.cfm/id/6783




Post a Comment

Featured Products From the ProHealth Store
Optimized Curcumin Longvida® Vitamin D3 Extreme™ Mitochondria Ignite™ with NT Factor®


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid

Natural Remedies

Olea25 Olive Hydroxytyrosol Hits Astonishing 68,000+ ORAC Antioxidant Value Olea25 Olive Hydroxytyrosol Hits Astonishing 68,000+ ORAC Antioxidant Value
Sunshine Vitamin Has D-lightful Health Benefits Sunshine Vitamin Has D-lightful Health Benefits
Improve Cardiovascular and Metabolic Health with Omega-7 Improve Cardiovascular and Metabolic Health with Omega-7
Break Free From Fibromyalgia Break Free From Fibromyalgia
Vitamin K-2 – A Key Player in Cardiovascular and Bone Health Vitamin K-2 – A Key Player in Cardiovascular and Bone Health

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map